| J9271 | Injection, pembrolizumab, 1 mg | 1 | 10 | 770 | $7,180 | $7.1M |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 28 | 260 | 1,330 | $240 | $3.5M |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 39 | 260 | 3,030 | $190 | $3.4M |
| J9306 | Injection, pertuzumab, 1 mg | 1 | 10 | 500 | $5,420 | $2.7M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 36 | 260 | 2,600 | $170 | $2.6M |
| 74177 | The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs. | 18 | 180 | 1,490 | $320 | $2.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 15 | 110 | 960 | $70 | $1.7M |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 1 | 10 | 410 | $1,540 | $1.6M |
| J9299 | Injection, nivolumab, 1 mg | 2 | 10 | 390 | $3,740 | $1.4M |
| J2505 | Injection, pegfilgrastim, 6 mg | 1 | 10 | 450 | $3,170 | $1.3M |